Patents Assigned to Beckley Psytech Limited
-
Patent number: 12534441Abstract: This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.Type: GrantFiled: January 17, 2022Date of Patent: January 27, 2026Assignee: Beckley Psytech LimitedInventors: Massimo Muratore, Amir Lotfi Moghaddam, Vinod Vishwapathi, Christopher Wong, Oliver Mcgaw
-
Patent number: 12275735Abstract: This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.Type: GrantFiled: September 7, 2023Date of Patent: April 15, 2025Assignee: Beckley Psytech LimitedInventors: Massimo Muratore, Amir Lotfi Moghaddam, Christopher Wong
-
Patent number: 12264131Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.Type: GrantFiled: August 4, 2023Date of Patent: April 1, 2025Assignee: Beckley Psytech LimitedInventors: Jason Gray, Susana Del Rio Gancedo, Dita Davis, David James Pearson, Daniel Rixson
-
Patent number: 12246005Abstract: The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.Type: GrantFiled: March 15, 2024Date of Patent: March 11, 2025Assignee: Beckley Psytech LimitedInventor: Jason Gray
-
Patent number: 11980605Abstract: The present invention provides a dry powder formulation of 5-MeO-DMT or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. The formulations described herein may be used to treat a disease or condition, such as depression or alcohol use disorder in a subject in need thereof.Type: GrantFiled: August 1, 2023Date of Patent: May 14, 2024Assignee: Beckley Psytech LimitedInventor: Jason Gray
-
Publication number: 20240116936Abstract: This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.Type: ApplicationFiled: September 7, 2023Publication date: April 11, 2024Applicant: BECKLEY PSYTECH LIMITEDInventors: Massimo MURATORE, Amir Lotfi MOGHADDAM, Christopher WONG
-
Publication number: 20240101514Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.Type: ApplicationFiled: August 4, 2023Publication date: March 28, 2024Applicant: BECKLEY PSYTECH LIMITEDInventors: Jason GRAY, Susana DEL RIO GANCEDO, Dita DAVIS, David James PEARSON, Daniel RIXSON
-
Publication number: 20230382858Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.Type: ApplicationFiled: May 2, 2023Publication date: November 30, 2023Applicant: Beckley Psytech LimitedInventors: Cosmo FEILDING-MELLEN, Timothy MASON
-
Publication number: 20230348381Abstract: A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).Type: ApplicationFiled: February 1, 2023Publication date: November 2, 2023Applicant: Beckley Psytech LimitedInventors: Cosmo FEILDING-MELLEN, Timothy MASON
-
Patent number: 11787806Abstract: This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.Type: GrantFiled: September 16, 2022Date of Patent: October 17, 2023Assignee: BECKLEY PSYTECH LIMITEDInventors: Massimo Muratore, Amir Lotfi Moghaddam, Christopher Wong
-
Patent number: 11773063Abstract: Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.Type: GrantFiled: September 9, 2022Date of Patent: October 3, 2023Assignee: Beckley Psytech LimitedInventors: Jason Gray, Susana Del Rio Gancedo, Dita Davis, David James Pearson, Daniel Rixson
-
Patent number: 11697651Abstract: This invention relates to pharmaceutically acceptable ergoline analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.Type: GrantFiled: September 9, 2022Date of Patent: July 11, 2023Assignee: BECKLEY PSYTECH LIMITEDInventors: Massimo Muratore, Amir Lotfi Moghaddam, Christopher Wong
-
Patent number: 11680044Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.Type: GrantFiled: September 26, 2022Date of Patent: June 20, 2023Assignee: Beckley Psytech LimitedInventors: Cosmo Feilding-Mellen, Timothy Mason
-
Patent number: 11603353Abstract: A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).Type: GrantFiled: August 4, 2022Date of Patent: March 14, 2023Assignee: Beckley Psytech LimitedInventors: Cosmo Feilding-Mellen, Timothy Mason
-
Publication number: 20230031944Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.Type: ApplicationFiled: September 26, 2022Publication date: February 2, 2023Applicant: Beckley Psytech LimitedInventors: Cosmo FEILDING-MELLEN, Timothy MASON
-
Publication number: 20220396552Abstract: A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).Type: ApplicationFiled: August 4, 2022Publication date: December 15, 2022Applicant: Beckley Psytech LimitedInventors: Cosmo FEILDING-MELLEN, Timothy MASON
-
Patent number: 11518743Abstract: An intranasal composition comprising a dosage amount of 50-150 mg/ml 5-methoxy-N,N-dimethyltryptamine (5MeODMT) in a liquid medium, wherein the 5MeODMT is formulated as the chloride salt of 5MeODMT (5MeODMT hydrochloride) and wherein the 5MeODMT hydrochloride is crystalline and characterised by one or more of: peaks in an XRPD diffractogram; an endothermic event in a DSC thermograph; an onset of decomposition in a TGA thermograph; and a DVS isotherm profile.Type: GrantFiled: April 27, 2022Date of Patent: December 6, 2022Assignee: Beckley Psytech LimitedInventors: Cosmo Feilding-Mellen, Timothy Mason
-
Patent number: 11518742Abstract: A composition comprising a pharmaceutically effective amount of a pharmaceutically acceptable benzoate salt of 5-methoxy-N,N-dimethyltryptamine (5MeODMT).Type: GrantFiled: April 27, 2022Date of Patent: December 6, 2022Assignee: Beckley Psytech LimitedInventors: Cosmo Feilding-Mellen, Timothy Mason
